Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary endpoints. LP-184 demonstrated clinical benefit in multiple highly aggressive...Read more
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and tolerability profile...Read more
Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in...Read more
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit from...Read more
NDA to be Submitted on a Rolling Basis, Beginning Early 2026 PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal...Read more
MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Vertex Pharmaceuticals | 27.61 6.37 | $460.76 |
| Capricor Therapeutics | 21.47 337.58 | $27.83 |
| UnitedHealth | 15.03 4.63 | $339.57 |
| Humana | 14.40 5.95 | $256.37 |
| West Pharmaceutical | 10.59 3.88 | $283.62 |
| Charles River Laboratories | 10.56 6.04 | $185.32 |
| Arrowhead Pharmaceuticals | 7.73 13.34 | $65.68 |
| Spruce Biosciences | 7.69 8.62 | $96.89 |
| Amgen | 7.64 2.26 | $346.00 |
| United Therapeutics | 7.49 1.58 | $481.63 |
| Sutro Biopharma | 7.25 992.77 | $7.98 |
| Praxis Precision Medicines | 7.24 4.04 | $186.36 |
| ICON | 6.71 3.66 | $189.85 |
| Movano Health | 6.44 207.07 | $9.55 |
| AbbVie | 6.07 2.71 | $230.44 |
| Apogee Therapeutics | 5.56 8.04 | $74.69 |
| Madrigal Pharmaceuticals | 5.13 0.90 | $578.29 |
| Bolt Biotherapeutics | 4.72 844.54 | $5.28 |
| Company | Volume | Last Trade |
|---|---|---|
| Virax Biolabs | 592,666,623 | $0.64 |
| Incannex Healthcare | 532,010,663 | $0.47 |
| Clearmind Medicine | 85,918,885 | $0.11 |
| Immuron | 73,608,070 | $1.56 |
| Capricor Therapeutics | 68,193,743 | $27.83 |
| Artelo Biosciences | 58,025,175 | $1.71 |
| Sangamo Therapeutics | 42,581,338 | $0.48 |
| Pfizer | 37,125,452 | $25.72 |
| Recursion | 29,818,875 | $4.61 |
| Acadia Healthcare | 29,782,851 | $14.64 |
| Black Diamond Therapeutics | 26,385,818 | $2.58 |
| ImmunityBio | 21,194,541 | $2.19 |
| Fractyl Health | 21,111,746 | $1.88 |
| Bristol-Myers Squibb | 19,578,590 | $51.17 |
| Mereo BioPharma | 19,260,337 | $1.94 |
| Ocugen | 17,641,954 | $1.20 |
| ProPhase Labs | 17,478,671 | $0.14 |
| Geron | 16,716,185 | $1.28 |
| Palisade Bio | 15,296,285 | $1.67 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
